Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

BACKGROUND: Results from large randomised controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged. In order to investigate the effects of these therapies and to respond to emerging evidence, we aimed to systematically review al...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet Oncol
Auteurs principaux: Vale, Claire L, Burdett, Sarah, Rydzewska, Larysa H M, Albiges, Laurence, Clarke, Noel W, Fisher, David, Fizazi, Karim, Gravis, Gwenaelle, James, Nicholas D, Mason, Malcolm D, Parmar, Mahesh K B, Sweeney, Christopher J, Sydes, Matthew R, Tombal, Bertrand, Tierney, Jayne F
Format: Artigo
Langue:Inglês
Publié: Lancet Pub. Group 2016
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4737894/
https://ncbi.nlm.nih.gov/pubmed/26718929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00489-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires